If you are searching for ARPA-H grants, start with the fact that trips up almost every applicant: ARPA-H rarely awards grants. The Advanced Research Projects Agency for Health has the legal authority to issue them, but the agency tells proposers plainly that it funds research through Other Transactions and cooperative agreements instead. That one distinction changes how you apply, how you get paid, and whether your project survives past its first milestone.

Why ARPA-H Doesn’t Really Do Grants

The most useful thing to understand about ARPA-H grants is that the agency calls them something else. In its own submission FAQs, ARPA-H states: “Unlike some funding agencies, ARPA-H does not provide grants to support research. Instead, we employ a range of alternative contract mechanisms.” The legal backbone is 42 U.S.C. 290c, which gives ARPA-H authority to award Other Transactions, cooperative agreements, grants, procurement contracts, and cash prizes. In practice, it leans on Other Transactions and cooperative agreements.

An Other Transaction is not a grant and not a standard procurement contract. It is a negotiated, performance-based agreement that lets the government set custom terms on budget, intellectual property, milestones, and timelines. The trade-off is real: OTs give you flexibility and speed, but funding is tied to “aggressive research milestones,” and when a project misses them, the agency ends it quickly and redirects the money. ARPA-H’s own budget documents describe this as the discipline that makes the model work. If you walk in expecting a multi-year grant that pays out on a fixed schedule regardless of progress, the OT model will surprise you.

This matters before you write a single word of a proposal. The review path, the negotiation, the payment structure, and the reporting obligations all follow contract logic, not grant logic. Treating an ARPA-H opportunity like an NIH R01 is the fastest way to waste a submission.

There is a second consequence most applicants miss. Because Other Transactions are negotiated rather than awarded off a fixed rulebook, the terms you accept become binding quickly — including intellectual property rights, data-sharing obligations, and the milestones that trigger each payment. There is far less room to renegotiate after the fact than there is in a standard grant. That puts a premium on understanding what you are agreeing to before the award is signed, ideally with someone who has read an OT term sheet before.

The Four Doors Into ARPA-H Funding

ARPA-H funding is not one application. It is four distinct tracks, and choosing the wrong one is a common early mistake. The first door is Programs — goal-driven efforts led by a Program Manager and announced for a limited time. The second is Initiatives, special targeted investments designed to move from proposal to funded contract quickly across a range of topics. The third is Mission Office ISOs, which accept ideas on a rolling basis for projects that fit the agency’s focus areas but fall outside a specific program. The fourth is Small Business, delivered as SBIR and STTR awards on specific topics.

The Mission Office door is organized around four offices rather than diseases: Health Science Futures, Proactive Health, Resilient Systems, and Scalable Solutions. Each runs its own standing ISO, so if your idea aligns with a focus area but no open program fits, this is your entry point. If you are weighing federal R&D options more broadly, it helps to see how ARPA-H sits alongside other agencies in the federal grants landscape before you commit to a track.

Which Door Fits Your Project

Founders and small companies often belong in the Small Business track. In April 2026, ARPA-H announced contract awards to 15 small businesses across eight states, an investment of up to $28 million, spanning wearables, AI, diagnostics, and gene therapies. If you are a startup, the SBIR/STTR path — the same mechanism explained on OpenGrants’ SBIR and STTR hub — is usually your most direct shot. University teams and larger consortia more often fit Programs or Mission Office ISOs.

One practical filter: read the agency’s research focus areas before you decide a door. ARPA-H organizes its work around platform technologies that cut across many conditions rather than single diseases, so a project framed narrowly around one indication often reads as a poor fit even when the science is strong. Reframing the same work as a platform with broad applications can move it from “out of scope” to fundable. That framing decision belongs at the very start, not in a revision after your Solution Summary comes back.

How the Application Actually Works: Solution Summary First

ARPA-H runs a two-stage process, and the first stage is short. For most opportunities, you submit a Solution Summary — a brief abstract of your concept, goals, and potential impact — before you are allowed to write a full proposal. ARPA-H reviews the summary and tells you whether the idea is viable and of interest. For Mission Office ISOs, this step is mandatory: proposers must receive written feedback before submitting a full proposal, and a proposal sent without that feedback can be rejected outright.

Opportunities are posted and maintained on SAM.gov, the federal System for Award Management, and you submit through ARPA-H’s Solutions portal. A live example shows the rhythm: the BRAINS Innovative Solution Opening (ARPA-H-SOL-26-148) set Solution Summaries due July 9, 2026, with full proposals due August 6, 2026 for its first intake group, and a second intake running into early 2027. If you have never registered in the federal system, budget time for it — a missing or expired Unique Entity Identifier stalls more submissions than weak science does, which is why getting set up early in your funding research workflow pays off.

What ARPA-H Funds — and What It Rejects on Sight

ARPA-H is explicit that it wants “revolutionary, not evolutionary” work. The agency seeks high-impact platform technologies with applications across many conditions, and it expects multidisciplinary teams — biologists, engineers, AI specialists, and clinicians working together. Just as important is what it will not fund: basic research, incremental improvements, educational programming, and infrastructure are outside its focus areas. Pitching a careful extension of existing work is a near-automatic rejection here.

Recent programs show the appetite. In May 2026, ARPA-H launched the Intelligent Generator of Research (IGoR) program, a five-year effort to build an AI-powered research ecosystem that improves reproducibility across biomedical science. The agency also runs an Office of Commercialization that helps funded teams find venture capital and navigate regulatory pathways once a project “graduates.” If your work is bold, cross-disciplinary, and aimed at a leap rather than a step — and you can imagine it surviving in the market — it fits the model. For startups specifically, it is worth comparing this against other small business funding options so you do not over-index on a single agency.

The Money Picture: A Smaller, Milestone-Disciplined Budget

The funding environment is tightening. ARPA-H’s FY2027 Congressional Justification requests $945 million, a decrease of $555 million from the FY2026 enacted level. The agency notes it has invested more than $3 billion across two dozen-plus programs in roughly three years, and it frames the smaller request around discipline: milestone-gated contracts, rigorous oversight, and quick termination of efforts that stall.

For applicants, the practical read is that competition is sharpening and reviewers will reward tightly scoped, milestone-credible proposals over sprawling ambition. Build your project plan around clear go/no-go decision points, because that is exactly how your funding will be structured and re-evaluated. If milestone-based budgeting is new to you, that is the single skill most worth developing before you submit. In a tighter year, the teams that win ARPA-H grants are the ones whose plans read as credible execution, not aspiration.

Frequently Asked Questions

Does ARPA-H give grants to individuals?

Rarely, and usually not as grants. ARPA-H primarily makes Other Transactions and cooperative agreements to organizations — companies, universities, and research teams — rather than direct grants to individuals. While the agency holds statutory authority to issue grants, it states it does not generally use grants to support research, so an individual researcher typically participates through an institution or a company.

How is an ARPA-H Other Transaction different from an NIH grant?

An NIH grant follows fixed federal grant rules and pays on a set schedule. An ARPA-H Other Transaction is a negotiated, performance-based agreement: budget, intellectual property, and timeline are set in negotiation, and continued funding depends on hitting milestones. Miss them, and the agreement can end early. It is closer to a milestone-driven contract than a traditional grant.

Do I have to be a small business to win ARPA-H funding?

No. Small businesses have a dedicated SBIR/STTR track, but ARPA-H also funds universities, large companies, and multidisciplinary consortia through its Programs, Initiatives, and Mission Office ISOs. The right door depends on your organization type and how your idea maps to an open solicitation.

Where do I find open ARPA-H solicitations?

Start at the ARPA-H Open Funding Opportunities page, then follow the links to the specific Innovative Solution Opening on SAM.gov, where the agency posts and maintains its solicitations. Each ISO lists eligibility, deadlines, evaluation criteria, and the templates you need.

How long does ARPA-H funding last?

Most programs and efforts run two to six years, but funding is not guaranteed for the full term. Awards are milestone-gated, so continuation depends on meeting the performance targets negotiated at the start.

Bottom Line: Apply Like It’s a Contract, Not a Grant

The biggest advantage you can give yourself with ARPA-H grants is to stop thinking of them as grants. Pick the right door for your organization, lead with a tight Solution Summary, and structure your project around milestones you can actually hit — because that is how the money is awarded and how it is taken away. With the FY2027 request down to $945 million, the agency will be more selective, not less, and milestone credibility will separate funded teams from rejected ones.

If you are deciding between ARPA-H and more conventional federal or foundation funding, get a second read before you sink weeks into a Solution Summary. OpenGrants’ managed grant writing and funding strategy team can help you confirm whether ARPA-H’s Other Transaction model fits your project — or whether a traditional grant is the smarter first move.